Abstract
A phase II study of new anthracycline, THP, was conducted in 46 patients with hematological malignancies in a cooperative study. THP was given intravenously either at a dose of 13–34 mg/m2 for 3–5 consecutive days or 35–50 mg/m2 at 3–4 week intervals.
Of 21 patients with acute leukemia, complete response (CR) was observed in 3 patients and partial response (PR) in 4. Of 22 patients with malignant lymphoma, CR was observed in 2 and PR in 6.
The predominant toxicity was myelosuppression. Leukopenia was noted in 73% of patients and thrombocytopenia in 14%. Anorexia, nausea and vomiting were observed in 49%, 26% and 23%, respectively. Alopecia and acute cardiac toxicities were mild and recovered quickly on discontinuation of THP.
Thus, THP was found to be effective for acute leukemia and malignant lymphoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arcamone F, Cassinelli G, Fautin G, Grein A, Orezzi P, Poli C, Spalla C: Adriamycin, 1–4-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var.caesinus. Biotechnol Bioeng 11:1101–1109, 1969
Lefrak EA, Pina J, Rosenheim S, Gottlieb JA: A clinical pathologic analysis of Adriamycin cardiotoxicity. Cancer 32:302–314, 1973
Minow RA, Benjamin, RS, Gottlieb JA: Adramycin cardiomyopathy. An overview with determination of risk factor. Cancer Chemother Rep 6:195–201, 1975
Umezawa H, Takahashi Y, Kinoshita M, Naganawa H, Ishizuka M, Takeuchi T: Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot 32:1082–1084, 1979
Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y: 4′-0-Tetrahydropyranyl adriamycin as a potential new antitumor agent. Cancer Res 42:1462–1467, 1982
Umezawa H, Takahashi Y, Takeuchi T, Nakamura H, Iitaka Y, Tatsuta K: The absolute structure of THP-adriamycins. J Antibiot 37:1094–1097, 1984
Danchev D, Paintrand M, Hayat M, Bourut C, Mathe G: Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy. J Antibiot 32:1085–1086, 1979
Holland JF, Frei III E, Burchenal JH: Criteria for the evaluation of response to therapy of acute lekemia. Proceedings of the 16th international congress of the hematology, Grune and Stratton, New York. p213–214, 1958
Ogawa M, Miyamoto H, Inagaki J, Horikoshi M, Ezaki K, Inoue K, Ikeda K, Usui N, Nakada H: Phase I clinical trial of a new anthracycline: 4′ -0-tetrahydropyranyl adriamycin. Invest New Drugs 1:169–172, 1983
Majima H: Exploratory clinical study of 4′ -0-tetrahydropyranyl Doxorubicin (THP-ADM)-Phase I-(in Japanese). Jpn J Cancer Chemother 10:134–140, 1983
Weil M, Glidewell O, Jacquillat C, Levy R, Serpick A, Wiernik P, Cuttner J, Hoogstraten B, Wasserman L, Ellison R, Gailani S, Brunner K, Silver R, Rege V, Cooper R, Lowenstein L, Nissen N, Haurani F, Blom J, Boiron M, Bernard J, Holland J: Daunorubicin in the therapy of acute Granulocytic leukemia. Cancer 33:921–928, 1973
Wiernick PH: Use of adriamycin (NSC-123127) in hématologic malignancies. Cancer Chemother Rep 3:369–373, 1975
Nakata H, Ogawa I, Miyamoto H, Inagaki J, Horikoshi N, Inoue K, Ikeda K, Usui N, Adachi K, Okada Y: Phase II study of 4′ -0-tetrahydropyranyladriamycin (THP-ADM). (in Japanese) Jpn J Cancer Chemother 11:138–142, 1984
Tani Y, Hirayama F, Ogawa H, Hashimoto K, Kubota Y, Kanakura Y, Oguma S, Ueda T, Nakamura H, Shibata H, Masaoka T: Early Phase II study of THP-ADM in acute leukemia (in Japanese) Jpn J Cancer Chemother 11:2573–2574, 1983
Takagi T, Oguro M, Iwabuchi K: Effects of single administration of tetrahydropyranyl adriamycin (THP) in lymphoid malignancy (in Japanese). Jpn J Cancer Chemother 11:1450–1456, 1984
Okuma K, Furuta I, Ota K: Acute cadiotoxicity of anthracyclines-analysis by using Holter ECG-. (in Japanese) Jpn J Cancer Chemother 11:902–911, 1984
Majima H: Preliminary Phase II study of 4′-0-tetrahydropyranyl doxurubicin (THP-ADM). (in Japanese) Jpn J Cancer Chemother 10:805–810, 1983
Kunimoto S, Miura K, Takahashi Y, Takeuchi T, Umezawa H: Rapid uptake by cultured tumor cells and intracellular behavior of 4′-0-tetrahydropyranyl adriamycin. J Antibiot 36:312–317, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yamada, K., Shirakawa, S., Ohno, R. et al. A phase II study of (2″ R)-4′ -0-tetrahydropyranyladriamycin (THP) in hematological malignancies. Invest New Drugs 5, 299–305 (1987). https://doi.org/10.1007/BF00175302
Issue Date:
DOI: https://doi.org/10.1007/BF00175302